Sort   by:  
 Page size 
MetabolomicsMicrobial Product Cocktails for Personalized Cancer Immunotherapy

The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers ample opportunities for developing effective i...

2025-07-01 | MTBLS12666 | MetaboLights
MetabolomicsNanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resis...

2025-03-13 | MTBLS12284 | MetaboLights
MetabolomicsCirculating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

The effectiveness of immunotherapy varies among patients with advanced non-small cell lung cancer (NSCLC). Here we investigated the baseline immune status in stage IV NSCLC patients treated with anti-PD-1 plus chemotherapy to understand the immune mechanisms and unveil systemic markers associated...

2025-10-16 | MTBLS13150 | MetaboLights
MetabolomicsMulti-omics of the gut microbial ecosystem in the immunotherapy resistance in microsatellite instability-high gastrointestinal cancer patients
Despite the encouraging efficacy of anti-PD-1/PD-L1 immunotherapy in microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) advanced gastrointestinal cancer, many patients exhibit primary or acquired resistance. Using multi-omics approaches, we interrogated gut microbiome, blood meta...
2026-07-16 | MTBLS9021 | MetaboLights
MetabolomicsCorrelation between gut microbiota and their metabolites and the efficacy of chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer

Gut microbiota has been reported to be associated with the host’s immune system and immunotherapy response, as well as immune-related adverse events (irAEs). Additionally, gut microbial metabolites have various immunomodulatory effects. Our study focused on the differences in gut microbiota and t...

2025-12-23 | MTBLS13557 | MetaboLights
MetabolomicsIn Vivo CRISPR Screens Identify SLC1A5 as a Metabolic Barrier for Cancer Immunotherapy
Tumor metabolic reprogramming profoundly shapes antitumor immunity, but the mechanisms linking glutamine metabolism to immune evasion in hepatocellular carcinoma (HCC) remain incompletely understood. Here, we identify the glutamine transporter SLC1A5 as a tumor-intrinsic regulator of HCC progression...
2026-08-20 | MTBLS15401 | MetaboLights
MetabolomicsCaffeine Enhances Antitumor T-cell Activity via COL12A1/IDO1/Kyn axis and Sensitivity to Anti-PD-1 Immunotherapy in Colorectal Cancer
Metabolomic sequencing on supernatants from caffeine-treated and untreated tumor cells to identify which metabolites are involved in activating CD8+ T cells
2025-05-06 | MTBLS11623 | MetaboLights
TranscriptomicsDNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy
Cancers evade the immune system in order to grow or metastasise through the process of cancer immunoediting. While checkpoint inhibitor therapy has been effective for reactivating tumour immunity in some cancers, many solid cancers, including breast cancer, remain largely non-responsive. Understandi...
ORGANISM(S): Mus musculus 
2021-09-01 | E-MTAB-10027 | biostudies-arrayexpress
MetabolomicsMetabolomic analysis to assess response to immunotherapy for malignant brain tumors: Part 3
Not available
ORGANISM(S): Mus musculus 
ST002209 | MetabolomicsWorkbench
MetabolomicsMetabolomic analysis to assess response to immunotherapy for malignant brain tumors: Part 2
Not available
ORGANISM(S): Mus musculus 
ST002208 | MetabolomicsWorkbench
Sort   by:  
 Page size